First Horizon Advisors Inc. Sells 3,449 Shares of Abbott Laboratories $ABT

First Horizon Advisors Inc. lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 75,153 shares of the healthcare product maker’s stock after selling 3,449 shares during the period. First Horizon Advisors Inc.’s holdings in Abbott Laboratories were worth $10,222,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its stake in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Penserra Capital Management LLC boosted its position in shares of Abbott Laboratories by 35.1% during the 1st quarter. Penserra Capital Management LLC now owns 6,129 shares of the healthcare product maker’s stock valued at $812,000 after acquiring an additional 1,594 shares during the last quarter. U.S. Capital Wealth Advisors LLC boosted its position in shares of Abbott Laboratories by 8.8% during the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 20,121 shares of the healthcare product maker’s stock valued at $2,669,000 after acquiring an additional 1,624 shares during the last quarter. Trek Financial LLC lifted its position in Abbott Laboratories by 3.5% during the first quarter. Trek Financial LLC now owns 10,105 shares of the healthcare product maker’s stock valued at $1,340,000 after purchasing an additional 344 shares during the last quarter. Finally, Greenleaf Trust lifted its position in Abbott Laboratories by 3.6% during the first quarter. Greenleaf Trust now owns 99,302 shares of the healthcare product maker’s stock valued at $13,172,000 after purchasing an additional 3,459 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $124.62 on Thursday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a market capitalization of $216.70 billion, a P/E ratio of 15.62, a P/E/G ratio of 2.36 and a beta of 0.68. The stock has a 50 day moving average price of $131.04 and a 200 day moving average price of $131.48.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The firm had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. During the same period last year, the company earned $1.21 EPS. Abbott Laboratories’s quarterly revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.46% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently commented on ABT shares. Sanford C. Bernstein increased their price target on shares of Abbott Laboratories from $145.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Evercore ISI lowered their price objective on Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating for the company in a research note on Wednesday, October 15th. Jefferies Financial Group raised their price objective on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Morgan Stanley raised their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Finally, William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $147.00.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.